Effects of enoxaparin preparations on thrombin generation and their correlation with their anti-FXa activity

References

• Handoll HHG, Farrar MJ, McBirnie J, et al. Heparina, heparina de bajo peso molecular y métodos físicos para la prevención de la trombosis venosa profunda y la embolia pulmonar después de la cirugía de fractura de cadera (Revisión Cochrane). La Biblioteca Cochrane Plus, número 3, 2008. Oxford, Update Software Ltd
   Google Scholar
• Prandoni P. Prevention and treatment of venous thromboembolism with low molecular weight heparins: Clinical implications of the recent European guidelines. Thromb J 2008;9:6-13
   Google Scholar
• Baglin T, Barrowcliffe T, Cohen A, et al. Guidelines on the use and monitoring of heparin. Br J Haematol 2006;133:19-34
   PubMed Web of Science ®Google Scholar
• Girardi G. Heparin treatment in pregnancy loss: potential therapeutic benefits beyond anticoagulation. J Reprod Immunol 2005;66:45-51
   PubMed Web of Science ®Google Scholar
• Mousa SA. Heparin, low-molecular weight heparin, and derivatives in thrombosis, angiogenesis, and inflammation: emerging links. Semin Thromb Hemost 2007;33:524-33
   PubMed Web of Science ®Google Scholar
• Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost 2008;34:74-85
   PubMed Web of Science ®Google Scholar
• Frydman AM, Lara L, Leroux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-18
   PubMed Web of Science ®Google Scholar
• Duchemin Pan-Petesch B, Arnaud B, Blouch MT, et al. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008;99:767-73
   PubMed Web of Science ®Google Scholar
• Gosselin RC, King JH, Janatpour KA, et al. Variability of plasma antiXa activities with different lots of enoxaparin. Ann Pharmacother 2004;38:563-68
   PubMed Web of Science ®Google Scholar
• Azizi M, Veyssier-Belot C, Alhenc-Gelas M, et al. Comparison of biological activities of two low molecular weight heparins in 10 healthy volunteers. Br J Clin Pharmacol 1995;40:577-84
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002;32:249-3
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of anti-factor Xa and anti-factor IIa activities of low molecular weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007;5:955-62
   PubMed Web of Science ®Google Scholar
• Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb 2002;32:249-3
   PubMed Web of Science ®Google Scholar
• Kowalski E, Kopec M, Niewiarowski S. An evaluation of the euglobulin method for the determination of fibrinolysis. J Clin Pathol 1959;12:215-18
   PubMed Web of Science ®Google Scholar
• Duchemin J, Pan-Petesch B, Arnaud B, et al. Influence of coagulation factors and tissue factor concentration on the thrombin generation test in plasma. Thromb Haemost 2008;99:767-73
   PubMed Web of Science ®Google Scholar
• Altman R, Scazziota A, DE Lourdes Herrera M, et al. Recombinant factor VIIa reverses the inhibitory effect of aspirin or aspirin plus clopidogrel on in vitro thrombin generation. J Thromb Haemost 2006;4:2022-7
   PubMed Web of Science ®Google Scholar
• Collignon G, Frydman A, Caplain H, et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins – dalteparin, enoxaparin and nadroparin – administered subcutaneously in healthy volunteers. Thromb Haemost 1995;73:630-40
   PubMed Web of Science ®Google Scholar
• White RH, Ginsberg JS. Low molecular weight heparins: are they all the same? Br J Haematol 2003;121:12-20
   PubMed Web of Science ®Google Scholar
• Frydman AM, Lara L, Le roux Y, et al. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-18
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Soderberg K, Widlund L, et al. A comparative study of three low molecular weight heparins and unfractionated heparin in healthy volunteers. Thromb Haemost 1995;73:398-401
   PubMed Web of Science ®Google Scholar
• Berntorp E, Salvagno GL. Standardization and clinical utility of thrombin-generation assays. Semin Thromb Hemost 2008;34:670-82
   PubMed Web of Science ®Google Scholar
• van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol 2008;142:889-903
   PubMed Web of Science ®Google Scholar
• Dargaud Y, Luddington R, Gray E, et al. Effect of standardization and normalization on imprecision of calibrated automated thrombography: an international multicentre study. Br J Haematol 2007;139:303-9
   PubMed Web of Science ®Google Scholar
• De Smedt E, Wagenvoord R, Coen Hemker H. The technique of measuring thrombin generation with fluorogenic substrates: 3. The effects of sample dilution. Thromb Haemost 2009;101:165-70
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Depasse F, Busson J, et al. Towards a standardization of thrombin generation assessment: the influence of tissue factor, platelets and phospholipids concentration on the normavalues of Thrombogram-Thrombinoscope assay. Thromb J 2005;26:3-16
   Google Scholar
• Gerotziafas GT, Depasse F, Chakroun T, et al. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in vitro clotting of whole blood and platelet rich plasma. Blood Coagul Fibrinolysis 2004;15:149-56
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of the anti-factor Xa and anti-factor IIa activities of low molecular weight heparins upon the phases of thrombin generation. J Thromb Haemost 2007;5:955-62
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Elalamy I, Depasse F, et al. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban. J Thromb Haemost 2007;5:886-8
   PubMed Web of Science ®Google Scholar
• Tay L, Aboud M, Ward CM, et al. Comparative study of low molecular weight heparin monitoring by anti-Xa levels, overall haemostasis potential and calibrated automated thrombogram assays. J Thromb Haemost 2007;5:abstract number:P-T-097
   Google Scholar
• Pieters J, Lindhout T. The limited importance of Factor Xa inhibition to the anticoagulant property of heparin in thromboplastin activated plasma. Blood 1988;72:2048-52
   PubMed Web of Science ®Google Scholar
• Kuczka K, Harder S, Picard-Willems B, et al. Biomarkers and coagulation tests for assessing the biosimilarity of a generic low molecular weight heparin: results of a study in healthy subjects with enoxaparin. J Clin Pharmacol 2008;48:1189-96
   PubMed Web of Science ®Google Scholar
• Crowther M, Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med 2007;13:409-13
   PubMed Web of Science ®Google Scholar
• Brophy DF, Martin EJ, Gehr WB, et al. Thrombin generation time is a novel parameter for monitoring enoxaparin therapy in patients with end-stage renal disease. J Thromb Haemost 2006;4:372-6
   PubMed Web of Science ®Google Scholar
• Hemker HC, Al Dieri R, Béguin S. Laboratory monitoring of low-molecular-weight heparin therapy – part II. Monitoring LMWH therapy? For the moment a non-question. J Thromb Haemost 2005;3:571-3
   PubMed Web of Science ®Google Scholar
• Perez Ruizs A, Montes R, Carrasco P, et al. Effect of low molecular weight heparin, bemiparin and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002;8:65-71
   PubMed Web of Science ®Google Scholar
• Mousa SA. Heparin and low molecular weight heparin in thrombosis and beyond. Curr Opin Investig Drugs 2002;3:1181-6
   PubMedGoogle Scholar
• Depasse F, González de Suso MJ, Lagoutte I, et al. Comparative study of the pharmacokinetic profiles of two LMWHs – bemiparin (3500 IU, anti-Xa) and tinzaparin (4500 IU, anti-Xa) – administered subcutaneously to healthy male volunteers. Thromb Res 2003;109:109-17
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Söderberg K, Widlund L, et al. A comparative study of three low-molecular weight heparins (LMWH) and unfractionated heparin (UH) in healthy volunteers. Thromb Haemost 1995;73:398-401
   PubMed Web of Science ®Google Scholar
• EMEA/CHMP/BMWP/118264/2007: Guideline on Similar Biological Medicinal Products Containing Low-Molecular-Weight-Heparins. Available at: http://www.ema.europa.eu/pdfs/human/biosimilar/11826407enfin.pdf [Last accessed 15 August 2010]
   Google Scholar
• Gori AM, Pepe G, Attanasio M, et al. Tissue factor reduction and tissue factor pathway inhibitor release after heparin administration. Thromb Haemost 1999;81:589-93
   PubMed Web of Science ®Google Scholar
• Gouin-Thibault I, Pautas E, Depasse F, et al. Heparin-releasable TFPI is not depleted after repeated injections of tinzaparin at therapeutic dose for up to 30 days. J Thromb Haemost 2003;1:2694-5
   PubMed Web of Science ®Google Scholar
• Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor as individual pharmacological parameters of various heparins. Thromb Haemost 2001;85:824-9
   PubMed Web of Science ®Google Scholar
• Depasse F, Gonzalez de Suso MJ, Lagoutte I, et al. Comparative study of the pharmacokinetic profiles of two LMWHs – bemiparin (3500 IU, antiXa) and tinzaparin (4500 IU, antiXa) – administered subcutaneously to healthy male volunteers. Thromb Res 2003;109:109-17
   PubMed Web of Science ®Google Scholar
• Klöcking HP, Markward F. Pharmacological stimulation of t-PA release. Pharmazie 1994;49:227-30
   PubMed Web of Science ®Google Scholar
• Naumnik B, Pawlak K, Mysliwiec M. Unfractionated heparin but not enoxaparina causes delayed plasma PAI-1 depletion in hemodialysis patients: a prospective study. Clin Appl Thromb Hemost 2009;15:84-91
   PubMed Web of Science ®Google Scholar
• Nakamura R, Umemura K, Hashimoto H, et al. Less pronounced enhancement of thrombin dependent inactivation of plasminogen activator inhibitor type 1 by LMWH compared with unfractioned heparin. Thromb Haemost 2006;95:637-42
   PubMed Web of Science ®Google Scholar